ProStrakan sells Galapagos stake
This article was originally published in Scrip
Executive Summary
ProStrakanhas confirmed that it has sold its 7% stake in the Belgian drug development company Galapagos. Although the Scottish firm would not confirm the value of the sale, media reports have suggested that it secured around £4 million. ProStrakan, which acquired the stake in 2006, told Scrip that the sale of its stake last month would not alter its aim of breaking even by 2010. The company added that further details of the transaction would be disclosed in its interim results on August 21st.